Pacific Biosciences of California PACB Other Commercial Liabilities
Other Commercial Liabilities at other companies
Other financials
Where this comes from
Reported directly by Pacific Biosciences of California in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Pacific Biosciences of California’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacific Biosciences of California's other commercial liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pacific Biosciences of California's other commercial liabilities?
- Pacific Biosciences of California (PACB) reported other commercial liabilities of $33.9M in Q1 2026.
- How has Pacific Biosciences of California's other commercial liabilities changed year-over-year?
- Pacific Biosciences of California's other commercial liabilities increased by 15.6% year-over-year, from $29.34M to $33.9M.
- What is the long-term trend for Pacific Biosciences of California's other commercial liabilities?
- Over 5 years (2020 to 2025), Pacific Biosciences of California's other commercial liabilities has grown at a 14.2% compound annual growth rate (CAGR), from $17.35M to $33.65M.